Bayer's healthcare head refuses to back down over Nexavar
This article was originally published in Scrip
Executive Summary
Bayer will not be flexible on its pricing approach to its anticancer Nexavar (sorafenib) as it believes the current price offers fair value for the product, the company's head of healthcare Arthur Higgins said at its 2009 financial results.